New generation of natural, effective, high-precision antimicrobials based on bacteriophages, to target and eliminate harmful bacteria
Harnessing the full potential of phages to develop novel antimicrobial compounds
Our Solution
MEDEA Biopharma is a lead discovery biopharmaceutical company developing new generation of high precision microorganisms to kill harmful bacteria by using bacteriophages. MEDEA Biopharma validates bacterial targets, discovers effective bacteriophages and enables scalable tailored applications in various industry fields.
Founded by lead scientists
Rüdiger Trojok, Dr. Elene Kakabadze, Giorgi Khubua and Alexander Skripnik founded MEDEA Biopharma in 2022 to revolutionize bacterial infection treatment and solve the antibiotic resistance issue.
Rüdiger Trojok
Managing Director
Dr. Elene Kakabadze
Chief Scientific Officer
Giorgi Khubua
Managing Director
Our industries
Potential to tackle multiple fields by bacteriophages of MEDEA Biopharma with different application modalities
Animal Health
Sustainable antibacterial and hygiene solutions for animals based on bacteriophages.
Aquaculture
Bacteriophage-based sustainable antibacterial solutions for aquaculture.
Plants & Food
Bacteriophages as antimicrobial substances in food chain & plant protection.
Backed By
© Urheberrecht. Alle Rechte vorbehalten.
Wir benötigen Ihre Zustimmung zum Laden der Übersetzungen
Wir nutzen einen Drittanbieter-Service, um den Inhalt der Website zu übersetzen, der möglicherweise Daten über Ihre Aktivitäten sammelt. Bitte überprüfen Sie die Details in der Datenschutzerklärung und akzeptieren Sie den Dienst, um die Übersetzungen zu sehen.